
Conference Coverage
Trending on the Eye Care Network
RCA releases first State of Retina Care report
OT Roundup ep. 1: ADHD's eye link, MOGENRY's BLA, and myopia news
FAQ: What retina specialists need to know about the MOGENRY (MCO-010) BLA acceptance
Vienna calling: Inside the 26th EURETINA Congress
How screen time and eyelid health affect dry eye risk
Latest News

Vienna calling: Inside the 26th EURETINA Congress

The association between atrial fibrillation and the eye

Bausch + Lomb's SeeLyra femtosecond laser earns European CE mark

ESCRS 2026: When "dry eye” isn’t dry eye: a case-based look at corneal neuropathic pain

ESCRS 2026: The eye as a window into ADHD: emerging evidence and practical implications

Shorts










Digital Edition








Podcasts
Continuing Medical Education
All News

Mingo-Botín, MD, PhD, discusses ESCRS 2026 data on an EDOF IOL in post-LASIK eyes vs non-LASIK controls.

The 44th Congress of the ESCRS kicked off at ExCeL London with iNovation Day and the Opening Ceremony, setting the stage for a five-day programme.

Handheld IC1000 pairs rebound tonometry with camera-guided alignment

Ahead of the 44th ESCRS Congress in London, a look at the presbyopia-correcting IOL, glaucoma and dry eye disease research on this year's scientific programme.

New research covers a 3D OCT foundation model, an OCTA biomarker review and offline smartphone screening for three retinal diseases.

A gamified program may speed the brain’s adjustment, new data suggest.

When to retest for inherited retinal dystrophies
João Pedro Marques, MD, PhD, on how systematic reanalysis moved a cohort's solved rate from 59.4% to 70.1% and what it means for gene therapy eligibility

A systematic review of 21 studies found OCTA detects early diabetic retinopathy—reduced vessel density being the most consistent biomarker—but heterogeneous, unstandardized evidence isn't sufficient for routine clinical screening yet.

Japan designated gildeuretinol an orphan drug for Stargardt disease as the oral therapy enters phase 3 evaluation in the NORTHSTAR trial.

A preclinical study of the effects of aflibercept (Eylea, Regeneron Pharmaceuticals) and faricimab (Vabysmo-svoa, Genentech) showed that the two treatments were equal in their ability to maintain or restore the retinal endothelial barrier function and resultant visual integrity. Investigators attributed this result mainly to inhibiting vascular endothelial growth factor A165 from binding to its receptor.

Matias Iglicki, MD, PhD, on patient selection, technical pitfalls and why symmetry decides outcomes in flanged vs sutured fixation

Researchers in the UK have developed a new treatment approach for aniridia-related keratopathy (ARK), a rare genetic ocular disease, namely, a collagen scaffold that delivers limbal epithelial stem cells and stromal stem cells to the area affected by ARK. The treatment resulted in improved ocular surface scores and visual acuities.

AI model beats human graders at spotting glaucoma risk in UK population retinal photos, boosting accuracy and strengthening the case for scalable AI vision screening.

A maternal high-fat diet can negatively affect the retinal structure in mice.

In this Q&A from EDES 2026 in Milan, Piotr A. Woźniak, MD, PhD, discusses his real-world evidence study on a dry eye lubricating drop, including its effects on tear film stability.

















